Literature DB >> 498058

Acute nonlymphocytic leukemia and acute myeloproliferative syndrome following radiation therapy for non-Hodgkin's lymphoma and chronic lymphocytic leukemia: clinical studies.

J F O'Donnell, H D Brereton, F A Greco, H R Gralnick, R E Johnson.   

Abstract

Seven cases of acute nonlymphocytic leukemia (ANLL) and one case of a malignant myeloproliferative syndrome have been seen after extensive radiation therapy for non-Hodgkin's lymphoma or chronic lymphocytic leukemia. A myeloproliferative syndrome with abnormalities in granulocytic, erythrocytic, and thrombocytic cell lines was present in all patients and in seven patients preceded ANLL by 2--18 months. The median time to the development of ANLL after primary disease therapy was 61 months (33--98 range). The leukemia was extremely refractory to therapy and median survival after diagnosis of ANLL was two months (range 0--9 months). Leukemia was seen only in those patients who received multiple courses and multiple techniques of radiation therapy.

Entities:  

Mesh:

Year:  1979        PMID: 498058     DOI: 10.1002/1097-0142(197911)44:5<1930::aid-cncr2820440556>3.0.co;2-e

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  3 in total

1.  Acute leukemia in a patient cured of diffuse histiocytic lymphoma.

Authors:  J P Dutcher; P H Wiernik
Journal:  J Cancer Res Clin Oncol       Date:  1986       Impact factor: 4.553

2.  Chronic lymphocytic leukaemia terminating in acute myelofibrosis.

Authors:  A L Lennard; S J Proctor
Journal:  J Clin Pathol       Date:  1984-05       Impact factor: 3.411

Review 3.  Histologic verification of leukemia, myelodysplasia, and multiple myeloma diagnoses in patients in Ukraine, 1987-1998.

Authors:  Irina Dyagil; Mircea Adam; Gilbert W Beebe; J David Burch; Svetlana N Gaidukova; Daniel Gluzman; Natalia Gudzenko; Victor Klimenko; LoAnn Peterson; Robert F Reiss; Stuart C Finch
Journal:  Int J Hematol       Date:  2002-07       Impact factor: 2.490

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.